Interventional, Open-label, Single-group, Long-term Follow-up Trial of Lu AG22515 in Patients With Moderate-to-severe Thyroid Eye Disease
Latest Information Update: 01 Oct 2025
At a glance
- Drugs APB-A1 (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Sponsors Lundbeck A/S
Most Recent Events
- 09 May 2025 Planned End Date changed from 15 Sep 2026 to 29 Sep 2026.
- 09 May 2025 Planned primary completion date changed from 15 Jan 2026 to 30 Mar 2026.
- 15 Oct 2024 Status changed from not yet recruiting to recruiting.